Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Alecensa
2. Alectinib
3. Ch5424802
4. Ro5424802
1. 1256589-74-8
2. Af-802 Hydrochloride
3. Alectinib Hcl
4. Alecensa
5. P9yy73lo6j
6. Alectinib Hydrochloride (jan)
7. Alectinib (hydrochloride)
8. Ch5424802 (hydrochloride)
9. Schembl14991271
10. 5h-benzo[b]carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-, Hydrochloride (1:1)
11. Alectinib Hydrochloride [jan]
12. 9-ethyl-6,6-dimethyl-8-[4-(morpholin-4-yl)piperidin-1-yl]-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile Hydrochloride
13. Unii-p9yy73lo6j
14. Alecensa (tn)
15. 5h-benzo(b)carbazole-3-carbonitrile, 9-ethyl-6,11-dihydro-6,6-dimethyl-8-(4-(4-morpholinyl)-1-piperidinyl)-11-oxo-, Hydrochloride (1:1)
16. Alectinib Monohydrochloride
17. Af-802 (hydrochloride)
18. Agn-pc-09o9bf
19. Ro5424802 (hydrochloride)
20. Chembl3707320
21. Chebi:62268
22. Ch5424802 Hcl
23. Dtxsid10154841
24. Ch 5424802, Alectinib Hcl
25. Bcp09075
26. Ex-a1553
27. Alectinib Hydrochloride [mi]
28. Ch-5424802 Hydrochloride
29. Hy-13011a
30. Mfcd27987893
31. S5232
32. Ccg-264759
33. Cs-3480
34. Sb16516
35. Alectinib Hydrochloride [who-dd]
36. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazole-3-carbonitrile,hydrochloride
37. Ac-29721
38. As-17062
39. Alectinib Hydrochloride [orange Book]
40. D10450
41. Q27104897
42. Ch5424802 Hcl Salt, Alectinib Hcl Salt, Af802 Hcl Salt
43. Ch-5428402 Hcl; Af-802 Hydrochloride; Rg-7853 Hydrochloride; Ro-5424802 Hydrochloride
44. 9-ethyl-6,11-dihydro-6,6-dimethyl-8-[4-(4-morpholinyl)-1-piperidinyl]-11-oxo-5h-benzo[b]carbazole-3-carbonitrile Hydrochloride (1:1)
45. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5h-benzo[b]carbazole-3-carbonitrile Monohydrochloride Salt
46. 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-ylpiperidin-1-yl)-11-oxo-5h-benzo[b]carbazole-3-carbonitrile;hydrochloride
47. Alectinib Hydrochloride;af-802 Hydrochloride;ch-5424802 Hydrochloride;rg-7853 Hydrochloride;ro-5424802 Hydrochloride
1. Alectinib
2. 1256580-46-7
3. Arq-761
4. Cas 1416163-60-4
5. Cas 1256580-46-7
Molecular Weight | 519.1 g/mol |
---|---|
Molecular Formula | C30H35ClN4O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 3 |
Exact Mass | 518.2448541 g/mol |
Monoisotopic Mass | 518.2448541 g/mol |
Topological Polar Surface Area | 72.4 Ų |
Heavy Atom Count | 37 |
Formal Charge | 0 |
Complexity | 867 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
Alecensa as monotherapy is indicated for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
Alecensa as monotherapy is indicated for the treatment of adult patients with ALKpositive advanced NSCLC previously treated with crizotinib.
L01ED03
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40093
Submission : 2024-06-13
Status : Active
Type : II
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-07-19
Pay. Date : 2019-05-28
DMF Number : 33637
Submission : 2019-02-28
Status : Active
Type : II
Date of Issue : 2022-09-02
Valid Till : 2025-05-05
Written Confirmation Number : WC-0349
Address of the Firm :
NDC Package Code : 54893-0087
Start Marketing Date : 2019-02-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 40093
Submission : 2024-06-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 33869
Submission : 2019-06-12
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 39383
Submission : 2024-01-30
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2019-07-19
Pay. Date : 2019-05-28
DMF Number : 33637
Submission : 2019-02-28
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2022-06-28
Pay. Date : 2022-03-15
DMF Number : 36908
Submission : 2022-03-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 34128
Submission : 2019-12-16
Status : Active
Type : II
About the Company : Porton Pharma Solutions Ltd. was founded in 2005, & the company's stock was successfully listed in Shenzhen Stock Exchange in 2014. Our R&D, manufacturing & operation facilities ar...
Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.
About the Company : Egis is a member of the Servier Group. Egis’ products are manufactured at 3 production sites in Hungary, which are certified by EMA,FDA, ANVISA, PMDA ,KFDA. Egis sells its produc...
Shuangda Pharmaceutical has a world-class first-class production line, having GMP, FDA and other regulatory certifications.
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has ...
Sichuan Elixir Pharmaceutical, a manufacturer of small molecule APIs & a CMO/CDMO service provider for anti-tumor characteristic APIs..
About the Company : Specializing in natural & oncology APIs, we establish R&D and production platforms for new salt, crystal form & synthetic biology research. We cooperate with clients for IND, NDA, ...
About the Company : Beijing Mesochem Technology Co. Ltd., which is located in the national economic and technological development area of Yizhuang, China, manufactures pharmaceutical chemicals, fine c...
About the Company : Cdymax (India) Pharma Private Limited was founded in 1994. The company's line of business includes the manufacturing, fabricating, or processing of drugs in pharmaceutical preparat...
About the Company : Divi's Laboratories Limited is a leading independent contract manufacturer of Active Pharmaceutical Ingredients and registered intermediates. We custom / exclusively manufacture fo...
About the Company : Hetero is a research based global pharmaceutical company focused on development, manufacturing and marketing of Active Pharmaceutical Ingredients (APIs), Intermediate Chemicals & F...
About the Company : Hunan Huateng Pharmaceutical Co., Ltd. is a research-based manufacturer and supplier of combinatorial building blocks, organics and fine chemicals, with 5000m2 laboratory and over ...
About the Company : NATCO PHARMA LIMITED was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million. With a modest beginning of operations as a single unit with 20 e...
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, approved by NICE authority for treating patients with ALK-positive early-stage NSCLC.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 21, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Roche’s Alecensa Receives NICE Recommendation to Treat ALK-Positive Lung Cancer
Details : Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, approved by NICE authority for treating patients with ALK-positive early-stage NSCLC.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2024
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, approved y MHLW authority for treating patients with ALK-positive early-stage NSCLC.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Chugai's Alecensa Approved in Japan for Adjuvant Treatment in Early-Stage ALK+ NSCLC
Details : Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, approved y MHLW authority for treating patients with ALK-positive early-stage NSCLC.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 29, 2024
Details:
Alecensa (alectinib) is a tyrosine kinase inhibitor that targets ALK and RET. It is used as adjuvant treatment after surgery in patients with early-stage ALK-positive non–small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: F. Hoffmann-La Roche
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Not Applicable
Deal Type : Not Applicable
Taiwan FDA approves Chugai’s Alecensa for the treatment of early stage ALK-positive NSCLC
Details : Alecensa (alectinib) is a tyrosine kinase inhibitor that targets ALK and RET. It is used as adjuvant treatment after surgery in patients with early-stage ALK-positive non–small cell lung cancer.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 03, 2024
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is now approved in EU for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EC Approves Roche’s Alecensa as First Adjuvant Treatment for ALK-Positive Lung Cancer
Details : Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is now approved in EU for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 10, 2024
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is under phase 3 clinical trials for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CHMP Recommends EU Approval Of Alecensa As Adjuvant Treatment For ALK-Positive Lung Cancer
Details : Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is under phase 3 clinical trials for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 30, 2024
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is now approved & indicated for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for ALK-Positive Lung Cancer
Details : Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is now approved & indicated for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 18, 2024
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is currentlt being evaluated in pediatric patients with ALK fusion-positive cancers.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: Phase I/ Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alectinib Deemed “Highly Promising” for Pediatric ALK Fusion-Positive Cancers
Details : Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is currentlt being evaluated in pediatric patients with ALK fusion-positive cancers.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 11, 2024
Details:
NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases is being evaluated in early-stage clinical trial in combination with Alectinib for the treatment of non-small cell lung cancer.
Lead Product(s): NXP900,Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: NXP900
Study Phase: PreclinicalProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Lead Product(s) : NXP900,Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Nuvectis' NXP900 Shows Strong Activity in Non-Small Lung Cancer Cells
Details : NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases is being evaluated in early-stage clinical trial in combination with Alectinib for the treatment of non-small cell lung cancer.
Brand Name : NXP900
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 08, 2024
Details:
Alecensa (alectinib) is a tyrosine kinase inhibitor that targets ALK and RET. It is use as adjuvant treatment after surgery in patients with early-stage ALK-positive non–small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2024
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
FDA Grants Priority Review to Adjuvant Alectinib for Early-Stage ALK+ NSCLC
Details : Alecensa (alectinib) is a tyrosine kinase inhibitor that targets ALK and RET. It is use as adjuvant treatment after surgery in patients with early-stage ALK-positive non–small cell lung cancer.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 31, 2024
Details:
Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is under phase 3 clinical trials for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Lead Product(s): Alectinib Hydrochloride
Therapeutic Area: Oncology Brand Name: Alecensa
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2023
Lead Product(s) : Alectinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Alecensa (alectinib) is an ALK tyrosine kinase receptor inhibitor, which is under phase 3 clinical trials for postoperative adjuvant therapy for ALK fusion gene-positive non-small cell lung cancer.
Brand Name : Alecensa
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2023
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?